| Entry |
|
|---|
| Name |
Momelotinib hydrochloride hydrate (JAN);
Momelotinib dihydrochloride monohydrate;
Ojjaara (TN);
Omjjara (TN) |
|---|
| Product |
|
|---|
| Formula |
C23H22N6O2. 2HCl. H2O
|
|---|
| Exact mass |
504.1443
|
|---|
| Mol weight |
505.39
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG02918 CYP2C8 substrate
DG01642 CYP2C9 substrate
DG01639 CYP2C19 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG01366): | D10889<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Janus kinase (JAK) inhibitor |
|---|
| Disease |
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP2C8 [HSA: 1558], CYP2C9 [HSA: 1559], CYP2C19 [HSA: 1557], CYP1A2 [HSA: 1544]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EJ Janus-associated kinase (JAK) inhibitors
L01EJ04 Momelotinib
D10889 Momelotinib hydrochloride hydrate (JAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Momelotinib
D10889 Momelotinib hydrochloride hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D10889 Momelotinib hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG01366 Momelotinib
D10889 Momelotinib hydrochloride hydrate
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01366 Momelotinib
D10889 Momelotinib hydrochloride hydrate
DG02918 CYP2C8 substrate
DG01366 Momelotinib
D10889 Momelotinib hydrochloride hydrate
DG01642 CYP2C9 substrate
DG01366 Momelotinib
D10889 Momelotinib hydrochloride hydrate
DG01639 CYP2C19 substrate
DG01366 Momelotinib
D10889 Momelotinib hydrochloride hydrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01366 Momelotinib
D10889 Momelotinib hydrochloride hydrate
Drug classes [BR:br08332]
Immunological agent
DG02020 JAK inhibitor
D10889 Momelotinib hydrochloride hydrate
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D10889 Momelotinib hydrochloride hydrate
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor serine/threonine kinases (RSTK)
TGFBR1 family
ACVR1 (ALK2)
D10889 Momelotinib hydrochloride hydrate (JAN) <JP/US>
Non-receptor tyrosine kinases
JAK family
JAK1
D10889 Momelotinib hydrochloride hydrate (JAN) <JP/US>
JAK2
D10889 Momelotinib hydrochloride hydrate (JAN) <JP/US>
JAK2* [HSA_VAR:3717v1]
D10889 Momelotinib hydrochloride hydrate (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10889
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10889
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10889
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10889
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10889
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10889
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG01366 Momelotinib
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01366 Momelotinib
DG02918 CYP2C8 substrate
DG01366 Momelotinib
DG01642 CYP2C9 substrate
DG01366 Momelotinib
DG01639 CYP2C19 substrate
DG01366 Momelotinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG01366 Momelotinib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 34
1 C1x C 8.3300 -18.3400
2 O2x O 8.3300 -19.7400
3 C1x C 9.5900 -20.4400
4 C1x C 10.7800 -19.7400
5 N1y N 10.7800 -18.3400
6 C1x C 9.5900 -17.5700
7 C8y C 12.0400 -17.5700
8 C8x C 13.2300 -18.2700
9 C8x C 14.4200 -17.5700
10 C8y C 14.4200 -16.1700
11 C8x C 13.2300 -15.4700
12 C8x C 12.0400 -16.1700
13 N1b N 15.6800 -15.4700
14 C8y C 16.8700 -16.1700
15 N5x N 16.8700 -17.5700
16 C8x C 18.0600 -18.2700
17 C8x C 19.3200 -17.5700
18 C8y C 19.3200 -16.1700
19 N5x N 18.0600 -15.4700
20 C8y C 20.5100 -15.4700
21 C8x C 21.7000 -16.1700
22 C8x C 22.8900 -15.4700
23 C8y C 22.8900 -14.0700
24 C8x C 21.7000 -13.3700
25 C8x C 20.5100 -14.0700
26 C5a C 24.1500 -13.3700
27 N1b N 25.3400 -14.0700
28 C1b C 26.5300 -13.3700
29 C3b C 27.7200 -14.0700
30 O5a O 24.1500 -11.9700
31 N3a N 28.9100 -14.7700
32 X Cl 26.2500 -19.1100
33 O0 O 22.4000 -19.1800
34 X Cl 26.2500 -19.1100
BOND 34
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 1
7 5 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 11 12 2
13 7 12 1
14 10 13 1
15 13 14 1
16 14 15 1
17 15 16 2
18 16 17 1
19 17 18 2
20 18 19 1
21 14 19 2
22 18 20 1
23 20 21 2
24 21 22 1
25 22 23 2
26 23 24 1
27 24 25 2
28 20 25 1
29 23 26 1
30 26 27 1
31 27 28 1
32 28 29 1
33 26 30 2
34 29 31 3
BRACKET 1 24.3600 -20.1600 24.3600 -17.9200
1 27.3000 -17.9200 27.3000 -20.1600
1 2
ORIGINAL 1 32
REPEAT 1 34
|
|---|
